Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK1 | P51617 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 9/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.34 |
| ▸ | WNT1 | P04628 | 1/20 | 0.34 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19274739 | 0.89 | LOXL2 (0.46) | IRAK1GSK3BDYRK1APDPK1MET | |
| SCHEMBL19259596 | 0.88 | PCSK9 (0.36) | IRAK1LOXL2PCSK9 | |
| SCHEMBL19274478 | 0.86 | PDPK1 (0.42) | DYRK1APDPK1 | |
| SCHEMBL29970064 | 0.85 | IRAK1 (0.46) | IRAK1GSK3BDYRK1APDPK1MET | |
| SCHEMBL19274598 | 0.85 | IRAK1 (0.46) | IRAK1GSK3BDYRK1APDPK1MET | |
| SCHEMBL20983582 | 0.81 | LOXL2 (0.38) | LOXL2 | |
| SCHEMBL19274642 | 0.81 | LOXL2 (0.42) | IRAK1GSK3BDYRK1APDPK1MET | |
| SCHEMBL19274863 | 0.80 | PDPK1 (0.41) | DYRK1APDPK1LOXL2 | |
| SCHEMBL19274725 | 0.80 | LOXL2 (0.43) | IRAK1GSK3BDYRK1APDPK1MET | |
| SCHEMBL19274609 | 0.80 | LOXL2 (0.44) | IRAK1GSK3BDYRK1APDPK1MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11608330-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2023-03-21 | — | — | US | disclosed |
| US-20220372028-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-11-24 | — | — | US | disclosed |
| US-10995088-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-05-04 | — | — | US | disclosed |
| US-20210040078-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-02-11 | — | — | US | disclosed |
| US-10807974-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-10-20 | — | — | US | disclosed |
| US-20190152966-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2019-05-23 | — | — | US | disclosed |
| WO-2017141049-A1 | METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152966-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | LOXL1, LOXL3, LOXL2 | IRAK1 983/4885GSK3B 921/4885DYRK1A 409/4885 |
| US-20210040078-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | LOXL1, LOXL3, LOXL2 | IRAK1 983/4885GSK3B 921/4885DYRK1A 409/4885 |
| US-20220372028-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | LOXL1, LOXL3, LOXL2 | IRAK1 983/4885GSK3B 921/4885DYRK1A 409/4885 |
| US-10995088-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | LOXL1, LOXL3, LOXL2 | IRAK1 983/4885GSK3B 921/4885DYRK1A 409/4885 |
| US-10807974-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | LOXL1, LOXL3, LOXL2 | IRAK1 983/4885GSK3B 921/4885DYRK1A 409/4885 |
| US-11608330-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | LOXL1, LOXL3, LOXL2 | IRAK1 983/4885GSK3B 921/4885DYRK1A 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.